Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.

Journal of virology - 1 Sept 2006

Gao Yanhua, Whitaker-Dowling Patricia, Watkins Simon C, Griffin Judith A, Bergman Ira

Abstract excerpt

Vesicular stomatitis virus (VSV) is being developed for cancer therapy. We created a recombinant replicating VSV (rrVSV) that preferentially infected Her2/neu-expressing breast cancer cells. This rrVSV did not express the native VSV-G glycoprotein (gp). Instead, it expressed a chimeric Sindbis gp which included a single-chain antibody (SCA) directed to the human Her2/neu receptor. The virus infected mouse mammary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma
Share to Chlorocebus aethiops
Share to COS Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoglobulin Fc Fragments

Share to Receptor, ErbB-2

Share to Serial Passage

Share to Vesicular stomatitis Indiana virus

Share to Viral Envelope Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 16912309
DOI: 10.1128/JVI.00142-06
PMCID: PMC1563842

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.PMID 16912309Read ↗

Oncolytic Therapy of Solid Tumors by Modified Vesicular Stomatitis VirusSemantic proximity Read ↗

Improved oncolytic activity of a reovirus mutant that displays enhanced virus spread due to reduced cell attachmentSemantic proximity Read ↗

Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.Semantic proximity Read ↗

Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteinsSemantic proximity Read ↗

Adaptive mutations in Sindbis virus E2 and Ross River virus E1 that allow efficient budding of chimeric viruses.Semantic proximity Read ↗

Characterization of Vesicular Stomatitis Virus Recombinants That Express and Incorporate High Levels of Hepatitis C Virus GlycoproteinsSemantic proximity Read ↗

Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Semantic proximity Read ↗

Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.Semantic proximity Read ↗

Growth and molecular evolution of vesicular stomatitis serotype New Jersey in cells derived from its natural insect-host: evidence for natural adaptation.Semantic proximity Read ↗

Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.Semantic proximity Read ↗

Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.